Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
| Autor: | Nicolas Sgarioto, Jean-Yves Masson, Noël J.-M. Raynal, Laura Sesma-Sanz, Stéphane Richard, Claudia Dominici, Zhenbao Yu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
And cytotoxic
Protein-Arginine N-Methyltransferases Methyltransferase Lung Neoplasms Combination therapy Cell Survival medicine.medical_treatment Antineoplastic Agents chemistry.chemical_compound Type I PRMT inhibitors Carcinoma Non-Small-Cell Lung Cell Line Tumor Genetics medicine Talazoparib Humans Pyrroles Enzyme Inhibitors Lung cancer Molecular Biology PARP inhibitors Genetics (clinical) Cells Cultured business.industry Research Cancer MTAP Drug Synergism Immunotherapy medicine.disease Ethylenediamines Synergy chemistry Non-small cell lung cancer cells Purine-Nucleoside Phosphorylase Drug resistance PARP inhibitor Cancer cell Cancer research DNA damage business Developmental Biology |
| Zdroj: | Clinical Epigenetics |
| ISSN: | 1868-7083 1868-7075 |
| Popis: | Background Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer-related death and represents a major health burden worldwide. Current therapies for NSCLC include chemotherapy, immunotherapy, and targeted molecular agents such as tyrosine kinase inhibitors and epigenetic drugs such as DNA methyltransferase inhibitors. However, survival rates remain low for patients with NSCLC, especially those with metastatic disease. A major cause for therapeutic failure is drug resistance, highlighting the need for novel therapies and combination strategies. Given that epigenetic modulators such as protein arginine methyltransferases (PRMTs) are frequently overexpressed in cancers, PRMT inhibitors are a promising class of cancer therapeutics. We screened a library of epigenetic and anticancer drugs to identify compounds that would synergize with MS023, a type I PRMT inhibitor, in decreasing the viability of methylthioadenosine phosphorylase (MTAP)-negative NSCLC cells. Results Among 181 compounds, we identified PARP inhibitors (PARPi) as having a strong synergistic interaction with type I PRMT inhibition. The combination of MS023 and the PARP inhibitor BMN-673 (Talazoparib) demonstrated strong synergistic interaction at low nanomolar concentrations in MTAP-negative NSCLC cell lines A549, SK-LU-1 and HCC4006. The re-introduction of MTAP decreased the sensitivity of the combination therapy in A549. The combination therapy resulted in elevated γ-H2AX foci indicating increased DNA damage causing decreased cell viability. Lastly, the combination therapy was effective in PARPi resistant ovarian cancer cells, suggesting that type I PRMT inhibitors could mitigate PARPi resistance, thus potentially having an important clinical impact for cancer treatment. Conclusions These findings identify a novel cancer drug combination therapy, which is more potent than the separate single-agent therapies. Thus, combining PARP inhibitors and type I PRMT inhibitors represents a new therapeutic opportunity for MTAP-negative NSCLC and certain cancer cells resistant to PARP inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink